AbobotulinumtoxinA: A Review in Pediatric Lower Limb Spasticity

  title={AbobotulinumtoxinA: A Review in Pediatric Lower Limb Spasticity},
  author={Yahiya Y. Syed},
  journal={Pediatric Drugs},
AbobotulinumtoxinA (Dysport®) is currently the only botulinum toxin A formulation approved by the US FDA for the treatment of lower limb spasticity in pediatric patients aged ≥2 years. Intramuscular abobotulinumtoxinA was approved based on the results of a pivotal phase 3 trial in children with lower limb spasticity due to cerebral palsy. In this trial, a single treatment cycle with abobotulinumtoxinA 10–15 U/kg/leg injected into the gastrocnemius and soleus muscles significantly improved ankle… 
2 Citations
Therapeutic possibilities of botulinum toxin in neurological disorders – treatment of limb spasticity in the course of brain damage
The study provides current evidence regarding the safety and efficacy of botulinum toxin injection for spasticity of the upper and lower limbs in both adults and children.
Botulinum Toxin: Techniques Within Pediatric Physiatry
Intramuscular botulinum toxin injections are used for treatment of focal spasticity in children, particularly in those with a diagnosis of cerebral palsy. There are a variety of techniques used when


AbobotulinumtoxinA Efficacy and Safety in Children With Equinus Foot Previously Treated With Botulinum Toxin.
The efficacy and safety of abobotulinumtoxinA treatment in these previously treated patients were comparable with the overall trial population, indicating that doses of 10 and 15 U/kg/leg are suitable starting doses for children with spasticity regardless of the previous botulinum toxin preparation used.
AbobotulinumtoxinA for Equinus Foot Deformity in Cerebral Palsy: A Randomized Controlled Trial
AbobotulinumtoxinA improves muscle tone in children with dynamic equinus resulting in an improved overall clinical impression and is well tolerated.
Estimation of botulinum toxin type A efficacy on spasticity and functional outcome in children with spastic cerebral palsy.
BTA treatment in CP children is followed by reduction in PMR values and improvement in functional motor status, and there was a significant increase in GMFM scores after 8 and 16 weeks from BTA application in both groups of patients.
Botulinum Toxin A (Dysport®)
Dysport®, a formulation of botulinum toxin A, blocks acetylcholine release at neuromuscular junctions causing denervation and temporary muscle paralysis, was generally well tolerated in patients with dystonias or focal spasticity and intramuscular Dysport® had limited efficacy.
AbobotulinumtoxinA (Dysport®) Improves Function According to Goal Attainment in Children With Dynamic Equinus Due to Cerebral Palsy
It is demonstrated that single injections of abobotulinumtoxinA (10 and 15 U/kg/leg) significantly improved the ability of pediatric cerebral palsy patients to achieve their functional goals.
Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study.
The safety profile of the toxin appears satisfactory and mean improvement in dynamic component was most pronounced in the 20 units/kg group, being equivalent to an increase in dorsiflexion with the knee extended at 19°, and was still present at 16 weeks.
Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment.
It is confirmed that BTX-A reduces spasticity and improves functional performance in standing and walking; association with casting provides more marked and enduring results.
Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A.
The results suggest that botulinum toxin A represents an effective and safe therapeutic substance for the treatment of pediatric patients suffering of focal motor problems due to dystonic or spastic muscular hyperactivity.
Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy
There was no evidence of cumulative or persisting benefit from repeated botulinum toxin A (BtA) at the injection cycle troughs at 1 year or 2 years, and BtA treatment can be viewed in the same light as other temporary measures to relieve spasticity, such as oral or intrathecal agents.
Spread of Botulinum Neurotoxin Type A at Standard Doses Is Inherent to the Successful Treatment of Spastic Equinus Foot in Cerebral Palsy
It is shown that botulinum toxin type A spreads from foot flexors to antagonist extensors and suggests that spread may be partly responsible for improving gait in children with cerebral palsy.